WHO Requests that Sinovac Share more Vaccine Data to Consider EUA

WHO Requests that Sinovac Share more Vaccine Data to Consider EUA

The World Health Organization (WHO) has requested that Chinese vaccine producer Sinovac Biotech (Nasdaq: SVA) share more data as they seek to assess whether to authorize a second Chinese SARS-CoV-2 vaccine for use around the world. Called CoronaVac, WHO specifically needs more information about safety and more granular details about the manufacturing processes employed by the company. WHO’s question: does Sinovac’s quality processes match those required by WHO for authorization? This is no trivial matter, as a great vaccine imbalance exists between rich and poor countries and another emergency authorized vaccine could make a material difference in closing that gap.

The Wall Street Journal reported on the requests recently. Last month, WHO gave the greenlight for the first time to a Chinese vaccine maker known as Sinopharm Group. While one insider at WHO suggests a CoronaVac decision may not occur until June, the urgency of the pandemic most certainly merits expedited review. Just a few weeks ago, the European Medicines Agency (EMA) initiated a rolling review of the Sinovac vaccine.

The CoronaVac is used by select countries in Asia, as well as South America, Mexico, and Europ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee